The third quarter saw a continuation of recent trends in biotech financing. There was a constant stream of IPOs (except in Europe) and venture capitalists continue to invest more into fewer companies. Valuations of IPOs remain high, even though six of the top ten companies that went public in the quarter have no data. The biotech NASDAQ index held its own compared to the other indices. The sector in Asia continues to grow, but with the vaccine scandal and growing tension due to tariffs, it displayed some volatility.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Q3 2018—The beat goes on. Nat Biotechnol 36, 1033 (2018). https://doi.org/10.1038/nbt.4295
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4295